

risk assessment. We now urgently require additional observational and epidemiologic studies to confirm or refute these initial projections. Such studies should be designed to clarify the bi-directional risk of blood exchanges during invasive procedures and to stratify that risk by the type of procedure, the circumstances of the procedure, and the skill and experience of the individual who performs it. Epidemiologic studies—both prospective and retrospective—must be completed to resolve the question of how frequently these observed blood exchanges actually lead to infection with bloodborne pathogens.

We distinguished in our position paper between the fact of HIV seropositivity itself and the potential for neurologic or other forms of impairment that might occur with chronic infection with HIV. Institutions should have in place policies under which all healthcare workers who have

physical, emotional, or neurologic impairments that may affect their fitness for certain aspects of work can be reviewed periodically and an appropriate determination made about necessary modifications of assigned tasks. State licensing boards also must make reasonable attempts to devise workable means for similar assessments of healthcare workers who function as independent contractors, in private offices, or in healthcare settings apart from institutional oversight. Since prejudice and fear continue to surround the HIV epidemic, institutions have a special responsibility to zealously guard the confidentiality of information regarding the serologic status of healthcare workers. Where seropositivity for any bloodborne pathogen has been determined, we find no requirement that individuals be required to disclose their status to any patient or colleague.

Since the publication of our position paper, the CDC has provided additional data regarding the possible transmission of HIV in a dentist's office practice. We have reviewed those data and concur with the likelihood that transmission of HIV did indeed occur in the course of dental practice. Whether such transmission occurred as a direct consequence of a major break in technique with blood contamination during an operative procedure, or whether such transmission occurred as a consequence of improper handling or inadequate sterilization of equipment remains unclear and probably will never be known with certainty. Such a rare transmission could have been and should have been anticipated, based on the hepatitis B model. Yet, all the existing serologic surveys reported to date from the professional practices of other HIV-infected healthcare workers performing invasive procedures have failed to demonstrate any evidence of transmission, emphasizing that the Florida case that has prompted so much concern remains at this moment a singular and unique event.

Major changes in healthcare policy should be based not on singular events, but rather on science, previous epidemiologic experience with other bloodborne pathogens, and a realistic assessment of the likelihood of a transmission occurring during a specific invasive procedure. Rather than hastening to mandatory programs of testing and practice restriction, we need additional studies, better engineering controls, better protective devices, and better training to enhance the safety of healthcare practice for patients and workers alike.

## **SHEA/CDC/AHA Hospital Epidemiology Training Program**

The SHEA/Centers for Disease Control (CDC)/American Hospital Association (AHA) Hospital Epidemiology Training Program will be held May 16-19, 1991, in Chicago, Illinois. The course is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These working sessions are supplemented with lectures and

seminars covering fundamental aspects of hospital epidemiology.

Donald Goldmann, MD, William Martone, MD, and Robert Weinstein, MD, and Gina Pugliese, RN, MS, will co-chair the program. Meeting, hotel, and travel arrangements will be available through the AHA. The registration fee for this program is \$495. The registration fee for infectious disease fellows is \$250 if the application is accompanied by proof of training status. For general registration information call the AI-IA (Phil Gordon) : (312) 280-6764.

# MEET JCAHO STANDARDS WITH NEW AICE®

Use the brand new version of the AICE® Software System to comply with the 1991 JCAHO Infection Control Standards

“Compliance” and “easy” are not words normally heard in the same sentence--not until the **AICE Software System** was developed to meet the complex demands of infection control. AICE enables compliance with the epidemiologic and statistical standards using an easy step-by-step model. Use AICE 4.0 to:

- ◆ Calculate specific infection rates (by surgeon, service, unit, etc.)
- ◆ Provide 3-way rate tables stratified by risk
- ◆ Easily feedback these rates to the employees/physicians who can make a difference
- ◆ Send follow-up lists and letters to physicians
- ◆ Conduct priority-directed/targeted, problem-oriented, and/or total house surveillance
- ◆ Identify clusters of infections on incidence graphs
- ◆ Track thresholds on graphic reports
- ◆ Perform case-control and special studies
- ◆ Compare hospital infections in-house with data trend analyses
- ◆ Watch the decline of infection rates and patient morbidity!

Does your hospital's operating room or mainframe computer have data that you would like to analyze in AICE? We have a solution for you:

Use our **Download Software** to transfer data from another computer into AICE! Then, analyze the data 16,000 different ways with the touch of a few buttons.

**AICE** is designed for both the novice and experienced computer user. With our 6 months of toll-free support, we will have you up and running on **AICE** in no time!

It is time to deal yourself a winning hand.



**Order AICE Today!**  
For more information write or call

*Come by our booth # 415 at APIC!*



Infection Control and  
Prevention Analysts, Inc.  
4425 South MoPac Expressway  
Suite 205  
Austin, TX 78735  
800-426-8015